Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 176


Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapy.

Zucca E, Rondeau S, Vanazzi A, Østenstad B, Mey UJM, Rauch D, Wahlin BE, Hitz F, Hernberg M, Johansson AS, de Nully Brown P, Hagberg H, Ferreri AJM, Lohri A, Novak U, Zander T, Bersvendsen H, Bargetzi M, Mingrone W, Krasniqi F, Dirnhofer S, Hayoz S, Hawle H, Berardi Vilei S, Ghielmini M, Kimby E.

Blood. 2019 May 17. pii: blood-2018-10-879643. doi: 10.1182/blood-2018-10-879643. [Epub ahead of print]


Incidence and inheritance of hyperphosphorylated paratarg-7 in patients with Waldenstrom's macroglobulinaemia in Sweden.

Brandefors L, Lindh J, Preuss KD, Fadle N, Pfreundschuh M, Kimby E.

Acta Oncol. 2019 Jun;58(6):824-827. doi: 10.1080/0284186X.2019.1582798. Epub 2019 Mar 19. No abstract available.


A clinico-molecular predictor identifies follicular lymphoma patients at risk of early transformation after first-line immunotherapy.

Steen CB, Leich E, Myklebust JH, Lockmer S, Wise JF, Wahlin BE, Østenstad B, Liestøl K, Kimby E, Rosenwald A, Smeland EB, Holte H, Lingjærde OC, Brodtkorb M.

Haematologica. 2019 Mar 7. pii: haematol.2018.209080. doi: 10.3324/haematol.2018.209080. [Epub ahead of print]


Reply to M. Sorigue et al.

Lockmer S, Østenstad B, Hagberg H, Holte H, Wahlin BE, Wader KF, Smedby KE, Brown P, Kimby E.

J Clin Oncol. 2019 Mar 20;37(9):759-760. doi: 10.1200/JCO.18.02362. Epub 2019 Feb 8. No abstract available.


TIGIT and PD-1 Mark Intratumoral T Cells with Reduced Effector Function in B-cell Non-Hodgkin Lymphoma.

Josefsson SE, Beiske K, Blaker YN, Førsund MS, Holte H, Østenstad B, Kimby E, Köksal H, Wälchli S, Bai B, Smeland EB, Levy R, Kolstad A, Huse K, Myklebust JH.

Cancer Immunol Res. 2019 Mar;7(3):355-362. doi: 10.1158/2326-6066.CIR-18-0351. Epub 2019 Jan 18.


Waldenström's macroglobulinaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Kastritis E, Leblond V, Dimopoulos MA, Kimby E, Staber P, Kersten MJ, Tedeschi A, Buske C.

Ann Oncol. 2019 May 1;30(5):860-862. doi: 10.1093/annonc/mdy466. No abstract available.


First-line therapy in chronic lymphocytic leukemia: a Swedish nation-wide real-world study on 1053 consecutive patients treated between 2007 and 2013.

Sylvan SE, Asklid A, Johansson H, Klintman J, Bjellvi J, Tolvgård S, Kimby E, Norin S, Andersson PO, Karlsson C, Karlsson K, Lauri B, Mattsson M, Sandstedt AB, Strandberg M, Österborg A, Hansson L.

Haematologica. 2019 Apr;104(4):797-804. doi: 10.3324/haematol.2018.200204. Epub 2018 Nov 22.


Chemotherapy-Free Initial Treatment of Advanced Indolent Lymphoma Has Durable Effect With Low Toxicity: Results From Two Nordic Lymphoma Group Trials With More Than 10 Years of Follow-Up.

Lockmer S, Østenstad B, Hagberg H, Holte H, Johansson AS, Wahlin BE, Wader KF, Steen CB, Meyer P, Maisenhølder M, Smedby KE, Brown P, Kimby E.

J Clin Oncol. 2018 Oct 4:JCO1800262. doi: 10.1200/JCO.18.00262. [Epub ahead of print]


Waldenström's macroglobulinaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Kastritis E, Leblond V, Dimopoulos MA, Kimby E, Staber P, Kersten MJ, Tedeschi A, Buske C; ESMO Guidelines Committee.

Ann Oncol. 2018 Oct 1;29(Supplement_4):iv270. doi: 10.1093/annonc/mdy322. No abstract available.


Prognostic factors and primary treatment for Waldenström macroglobulinemia - a Swedish Lymphoma Registry study.

Brandefors L, Melin B, Lindh J, Lundqvist K, Kimby E.

Br J Haematol. 2018 Nov;183(4):564-577. doi: 10.1111/bjh.15558. Epub 2018 Sep 10.


Ibrutinib induces rapid down-regulation of inflammatory markers and altered transcription of chronic lymphocytic leukaemia-related genes in blood and lymph nodes.

Palma M, Krstic A, Peña Perez L, Berglöf A, Meinke S, Wang Q, Blomberg KEM, Kamali-Moghaddam M, Shen Q, Jaremko G, Lundin J, De Paepe A, Höglund P, Kimby E, Österborg A, Månsson R, Smith CIE.

Br J Haematol. 2018 Oct;183(2):212-224. doi: 10.1111/bjh.15516. Epub 2018 Aug 20.


Rituximab and the risk of transformation of follicular lymphoma: a retrospective pooled analysis.

Federico M, Caballero Barrigón MD, Marcheselli L, Tarantino V, Manni M, Sarkozy C, Alonso-Álvarez S, Wondergem M, Cartron G, Lopez-Guillermo A, Issa D, Morschhauser F, Alcoceba M, Kimby E, Rusconi C, Chamuleau M, Holte H, Lockmer S, Montoto S, Gomes da Silva M, Aurer I, Zucca E, Paszkiewicz-Kozik E, Minoia C, Skrypets T, Blaker YN, Salles G, Coiffier B; Aristotle Consortium.

Lancet Haematol. 2018 Aug;5(8):e359-e367. doi: 10.1016/S2352-3026(18)30090-5. Epub 2018 Jul 4.


High-risk chronic lymphocytic leukemia in the era of pathway inhibitors: integrating molecular and cellular therapies.

Dreger P, Ghia P, Schetelig J, van Gelder M, Kimby E, Michallet M, Moreno C, Robak T, Stilgenbauer S, Montserrat E; European Research Initiative on CLL (ERIC) and the European Society for Blood and Marrow Transplantation (EBMT).

Blood. 2018 Aug 30;132(9):892-902. doi: 10.1182/blood-2018-01-826008. Epub 2018 Jul 11. Review.


Waldenström's macroglobulinaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Kastritis E, Leblond V, Dimopoulos MA, Kimby E, Staber P, Kersten MJ, Tedeschi A, Buske C; ESMO Guidelines Committee.

Ann Oncol. 2018 Oct 1;29(Supplement_4):iv41-iv50. doi: 10.1093/annonc/mdy146. No abstract available.


Pneumococcal conjugate vaccine triggers a better immune response than pneumococcal polysaccharide vaccine in patients with chronic lymphocytic leukemia A randomized study by the Swedish CLL group.

Svensson T, Kättström M, Hammarlund Y, Roth D, Andersson PO, Svensson M, Nilsson I, Rombo L, Cherif H, Kimby E.

Vaccine. 2018 Jun 14;36(25):3701-3707. doi: 10.1016/j.vaccine.2018.05.012. Epub 2018 May 7.


Rituximab: a benchmark in the development of chemotherapy-free treatment strategies for follicular lymphomas.

Karmali R, Kimby E, Ghielmini M, Flinn IW, Gordon LI, Zucca E.

Ann Oncol. 2018 Feb 1;29(2):332-340. doi: 10.1093/annonc/mdx768. Review.


Unmet needs in the scientific approach to older patients with lymphoma.

Bron D, Aurer I, André MPE, Bonnet C, Caballero D, Falandry C, Kimby E, Soubeyran P, Zucca E, Bosly A, Coiffier B; European Lymphoma Institute (ELI) Group and the EHA SWG “Aging and Hematology”.

Haematologica. 2017 Jun;102(6):972-975. doi: 10.3324/haematol.2017.167619. Review. No abstract available.


Prognostic relevance of CD163 and CD8 combined with EZH2 and gain of chromosome 18 in follicular lymphoma: a study by the Lunenburg Lymphoma Biomarker Consortium.

Stevens WBC, Mendeville M, Redd R, Clear AJ, Bladergroen R, Calaminici M, Rosenwald A, Hoster E, Hiddemann W, Gaulard P, Xerri L, Salles G, Klapper W, Pfreundschuh M, Jack A, Gascoyne RD, Natkunam Y, Advani R, Kimby E, Sander B, Sehn LH, Hagenbeek A, Raemaekers J, Gribben J, Kersten MJ, Ylstra B, Weller E, de Jong D.

Haematologica. 2017 Aug;102(8):1413-1423. doi: 10.3324/haematol.2017.165415. Epub 2017 Apr 14.


Erratum to "Higher T-cell imbalance and growth factor receptor expression in B-cell chronic lymphocytic leukemia (B-CLL) as compared to monoclonal B-cell lymphocytosis of undetermined significance (B-MLUS)" [Leukemia Res. 13(1) (1989) 31-37].

Garcia C, Rosén A, Kimby E, Aguilar-Santelises M, Jondal M, Björkholm M, Holm G, Mellstedt H.

Leuk Res. 2017 Jun;57:127. doi: 10.1016/j.leukres.2017.01.029. Epub 2017 Mar 15. No abstract available.


Targeting of B-cell receptor signalling in B-cell malignancies.

Jerkeman M, Hallek M, Dreyling M, Thieblemont C, Kimby E, Staudt L.

J Intern Med. 2017 Nov;282(5):415-428. doi: 10.1111/joim.12600. Epub 2017 Mar 14. Review.


Soluble CD52 is an indicator of disease activity in chronic lymphocytic leukemia.

Vojdeman FJ, Herman SEM, Kirkby N, Wiestner A, van T' Veer MB, Tjønnfjord GE, Itälä-Remes MA, Kimby E, Farooqui MZ, Polliack A, Wu KL, Doorduijn JK, Alemayehu WG, Wittebol S, Kozak T, Walewski J, Abrahamse-Testroote MCJ, van Oers MHJ, Geisler CH, Niemann CU.

Leuk Lymphoma. 2017 Oct;58(10):2356-2362. doi: 10.1080/10428194.2017.1285027. Epub 2017 Feb 7.


Safety and immunogenicity of inactivated varicella-zoster virus vaccine in adults with hematologic malignancies receiving treatment with anti-CD20 monoclonal antibodies.

Parrino J, McNeil SA, Lawrence SJ, Kimby E, Pagnoni MF, Stek JE, Zhao Y, Chan IS, Kaplan SS.

Vaccine. 2017 Mar 27;35(14):1764-1769. doi: 10.1016/j.vaccine.2016.10.055. Epub 2017 Mar 3.


Molecular Monitoring after Autologous Stem Cell Transplantation and Preemptive Rituximab Treatment of Molecular Relapse; Results from the Nordic Mantle Cell Lymphoma Studies (MCL2 and MCL3) with Median Follow-Up of 8.5 Years.

Kolstad A, Pedersen LB, Eskelund CW, Husby S, Grønbæk K, Jerkeman M, Laurell A, Räty R, Elonen E, Andersen NS, Brown PD, Kimby E, Bentzen H, Sundström C, Ehinger M, Karjalainen-Lindsberg ML, Delabie J, Ralfkiær E, Fagerli UM, Nilsson-Ehle H, Lauritzsen GF, Kuittinen O, Niemann C, Geisler CH; Nordic Lymphoma Group.

Biol Blood Marrow Transplant. 2017 Mar;23(3):428-435. doi: 10.1016/j.bbmt.2016.12.634. Epub 2016 Dec 27.


Thirty-Month Complete Response as a Surrogate End Point in First-Line Follicular Lymphoma Therapy: An Individual Patient-Level Analysis of Multiple Randomized Trials.

Shi Q, Flowers CR, Hiddemann W, Marcus R, Herold M, Hagenbeek A, Kimby E, Hochster H, Vitolo U, Peterson BA, Gyan E, Ghielmini M, Nielsen T, De Bedout S, Fu T, Valente N, Fowler NH, Hoster E, Ladetto M, Morschhauser F, Zucca E, Salles G, Sargent DJ.

J Clin Oncol. 2017 Feb 10;35(5):552-560. doi: 10.1200/JCO.2016.70.8651. Epub 2016 Dec 28.


Health-related quality of life and symptoms in patients with rituximab-refractory indolent non-Hodgkin lymphoma treated in the phase III GADOLIN study with obinutuzumab plus bendamustine versus bendamustine alone.

Cheson BD, Trask PC, Gribben JG, Dimier N, Kimby E, Lugtenburg PJ, Thieblemont C, Wassner-Fritsch E, Launonen A, Sehn LH.

Ann Hematol. 2017 Feb;96(2):253-259. doi: 10.1007/s00277-016-2878-5. Epub 2016 Nov 30.


15-year follow-up of the Second Nordic Mantle Cell Lymphoma trial (MCL2): prolonged remissions without survival plateau.

Eskelund CW, Kolstad A, Jerkeman M, Räty R, Laurell A, Eloranta S, Smedby KE, Husby S, Pedersen LB, Andersen NS, Eriksson M, Kimby E, Bentzen H, Kuittinen O, Lauritzsen GF, Nilsson-Ehle H, Ralfkiaer E, Ehinger M, Sundström C, Delabie J, Karjalainen-Lindsberg ML, Workman CT, Garde C, Elonen E, Brown P, Grønbaek K, Geisler CH.

Br J Haematol. 2016 Nov;175(3):410-418. doi: 10.1111/bjh.14241. Epub 2016 Jul 5.


Guideline for the diagnosis, treatment and response criteria for Bing-Neel syndrome.

Minnema MC, Kimby E, D'Sa S, Fornecker LM, Poulain S, Snijders TJ, Kastritis E, Kremer S, Fitsiori A, Simon L, Davi F, Lunn M, Castillo JJ, Patterson CJ, Le Garff-Tavernier M, Costopoulos M, Leblond V, Kersten MJ, Dimopoulos MA, Treon SP.

Haematologica. 2017 Jan;102(1):43-51. doi: 10.3324/haematol.2016.147728. Epub 2016 Oct 6.


The HOVON68 CLL trial revisited: performance status and comorbidity affect survival in elderly patients with chronic lymphocytic leukemia.

Vojdeman FJ, Van't Veer MB, Tjønnfjord GE, Itälä-Remes M, Kimby E, Polliack A, Wu KL, Doorduijn JK, Alemayehu WG, Wittebol S, Kozak T, Walewski J, Abrahamse-Testroote MC, van Oers MH, Geisler CH.

Leuk Lymphoma. 2017 Mar;58(3):594-600. doi: 10.1080/10428194.2016.1213831. Epub 2016 Aug 2. Erratum in: Leuk Lymphoma. 2017 Mar;58(3):758.


Treatment recommendations from the Eighth International Workshop on Waldenström's Macroglobulinemia.

Leblond V, Kastritis E, Advani R, Ansell SM, Buske C, Castillo JJ, García-Sanz R, Gertz M, Kimby E, Kyriakou C, Merlini G, Minnema MC, Morel P, Morra E, Rummel M, Wechalekar A, Patterson CJ, Treon SP, Dimopoulos MA.

Blood. 2016 Sep 8;128(10):1321-8. doi: 10.1182/blood-2016-04-711234. Epub 2016 Jul 18. Review.


Prophylactic immunoglobulin therapy in secondary immune deficiency - an expert opinion.

Agostini C, Blau IW, Kimby E, Plesner T.

Expert Rev Clin Immunol. 2016 Sep;12(9):921-6. doi: 10.1080/1744666X.2016.1208085. Epub 2016 Jul 14. Review.


Optimal use of bendamustine in hematologic disorders: Treatment recommendations from an international consensus panel - an update.

Cheson BD, Brugger W, Damaj G, Dreyling M, Kahl B, Kimby E, Ogura M, Weidmann E, Wendtner CM, Zinzani PL.

Leuk Lymphoma. 2016;57(4):766-82. doi: 10.3109/10428194.2015.1099647. Epub 2015 Nov 23. Review.


Familial Waldenstrom's macroglobulinemia and relation to immune defects, autoimmune diseases, and haematological malignancies--A population-based study from northern Sweden.

Brandefors L, Kimby E, Lundqvist K, Melin B, Lindh J.

Acta Oncol. 2016;55(1):91-8. doi: 10.3109/0284186X.2015.1096019. Epub 2015 Nov 11.


Targets for Ibrutinib Beyond B Cell Malignancies.

Berglöf A, Hamasy A, Meinke S, Palma M, Krstic A, Månsson R, Kimby E, Österborg A, Smith CI.

Scand J Immunol. 2015 Sep;82(3):208-17. doi: 10.1111/sji.12333. Review.


Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial.

Hillmen P, Robak T, Janssens A, Babu KG, Kloczko J, Grosicki S, Doubek M, Panagiotidis P, Kimby E, Schuh A, Pettitt AR, Boyd T, Montillo M, Gupta IV, Wright O, Dixon I, Carey JL, Chang CN, Lisby S, McKeown A, Offner F; COMPLEMENT 1 Study Investigators.

Lancet. 2015 May 9;385(9980):1873-83. doi: 10.1016/S0140-6736(15)60027-7. Epub 2015 Apr 14.


Two courses of four weekly infusions of rituximab with or without interferon-α2a: final results from a randomized phase III study in symptomatic indolent B-cell lymphomas.

Kimby E, Östenstad B, Brown P, Hagberg H, Erlanson M, Holte H, Linden O, Johansson AS, Ahlgren T, Wader K, Wahlin BE, Delabie J, Sundström C; Nordic Lymphoma Group (NLG).

Leuk Lymphoma. 2015;56(9):2598-607. doi: 10.3109/10428194.2015.1014363. Epub 2015 Mar 11.


Serum cytokines in follicular lymphoma.

Kimby E.

Blood. 2015 Feb 5;125(6):892-3. doi: 10.1182/blood-2014-12-615302. No abstract available.


Ofatumumab in poor-prognosis chronic lymphocytic leukemia: a phase IV, non-interventional, observational study from the European Research Initiative on Chronic Lymphocytic Leukemia.

Moreno C, Montillo M, Panayiotidis P, Dimou M, Bloor A, Dupuis J, Schuh A, Norin S, Geisler C, Hillmen P, Doubek M, Trněný M, Obrtlikova P, Laurenti L, Stilgenbauer S, Smolej L, Ghia P, Cymbalista F, Jaeger U, Stamatopoulos K, Stavroyianni N, Carrington P, Zouabi H, Leblond V, Gomez-Garcia JC, Rubio M, Marasca R, Musuraca G, Rigacci L, Farina L, Paolini R, Pospisilova S, Kimby E, Bradley C, Montserrat E.

Haematologica. 2015 Apr;100(4):511-6. doi: 10.3324/haematol.2014.118158. Epub 2015 Jan 16.


Perturbations of the endocannabinoid system in mantle cell lymphoma: correlations to clinical and pathological features.

Wasik AM, Nygren L, Almestrand S, Zong F, Flygare J, Wennerholm SB, Saft L, Andersson P, Kimby E, Wahlin BE, Christensson B, Sander B.

Oncoscience. 2014 Sep 4;1(8):550-7. eCollection 2014.


Managing high-risk CLL during transition to a new treatment era: stem cell transplantation or novel agents?

Dreger P, Schetelig J, Andersen N, Corradini P, van Gelder M, Gribben J, Kimby E, Michallet M, Moreno C, Stilgenbauer S, Montserrat E; European Research Initiative on CLL (ERIC) and the European Society for Blood and Marrow Transplantation (EBMT).

Blood. 2014 Dec 18;124(26):3841-9. doi: 10.1182/blood-2014-07-586826. Epub 2014 Oct 9. Review.


T-cell levels are prognostic in mantle cell lymphoma.

Nygren L, Wasik AM, Baumgartner-Wennerholm S, Jeppsson-Ahlberg Å, Klimkowska M, Andersson P, Buhrkuhl D, Christensson B, Kimby E, Wahlin BE, Sander B.

Clin Cancer Res. 2014 Dec 1;20(23):6096-104. doi: 10.1158/1078-0432.CCR-14-0889. Epub 2014 Oct 7.


Follicular lymphoma in Sweden: nationwide improved survival in the rituximab era, particularly in elderly women: a Swedish Lymphoma Registry study.

Junlén HR, Peterson S, Kimby E, Lockmer S, Lindén O, Nilsson-Ehle H, Erlanson M, Hagberg H, Rådlund A, Hagberg O, Wahlin BE.

Leukemia. 2015 Mar;29(3):668-76. doi: 10.1038/leu.2014.251. Epub 2014 Aug 25.


The EBMT/EMCL consensus project on the role of autologous and allogeneic stem cell transplantation in mantle cell lymphoma.

Robinson S, Dreger P, Caballero D, Corradini P, Geisler C, Ghielmini M, Le Gouill S, Kimby E, Rule S, Vitolo U, Dreyling M, Hermine O; European MCL Network and the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation.

Leukemia. 2015 Feb;29(2):464-73. doi: 10.1038/leu.2014.223. Epub 2014 Jul 18.


Treatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders: IWWM-7 consensus.

Dimopoulos MA, Kastritis E, Owen RG, Kyle RA, Landgren O, Morra E, Leleu X, García-Sanz R, Munshi N, Anderson KC, Terpos E, Ghobrial IM, Morel P, Maloney D, Rummel M, Leblond V, Advani RH, Gertz MA, Kyriakou C, Thomas SK, Barlogie B, Gregory SA, Kimby E, Merlini G, Treon SP.

Blood. 2014 Aug 28;124(9):1404-11. doi: 10.1182/blood-2014-03-565135. Epub 2014 Jul 15. Review.


Frontline low-dose alemtuzumab with fludarabine and cyclophosphamide prolongs progression-free survival in high-risk CLL.

Geisler CH, van T' Veer MB, Jurlander J, Walewski J, Tjønnfjord G, Itälä Remes M, Kimby E, Kozak T, Polliack A, Wu KL, Wittebol S, Abrahamse-Testroote MC, Doorduijn J, Ghidey Alemayehu W, van Oers MH.

Blood. 2014 May 22;123(21):3255-62. doi: 10.1182/blood-2014-01-547737. Epub 2014 Apr 15.


microRNA-34b/c on chromosome 11q23 is aberrantly methylated in chronic lymphocytic leukemia.

Deneberg S, Kanduri M, Ali D, Bengtzen S, Karimi M, Qu Y, Kimby E, Mansouri L, Rosenquist R, Lennartsson A, Lehmann S.

Epigenetics. 2014 Jun;9(6):910-7. doi: 10.4161/epi.28603. Epub 2014 Mar 31.


High-resolution chromatin immunoprecipitation (ChIP) sequencing reveals novel binding targets and prognostic role for SOX11 in mantle cell lymphoma.

Kuo PY, Leshchenko VV, Fazzari MJ, Perumal D, Gellen T, He T, Iqbal J, Baumgartner-Wennerholm S, Nygren L, Zhang F, Zhang W, Suh KS, Goy A, Yang DT, Chan WC, Kahl BS, Verma AK, Gascoyne RD, Kimby E, Sander B, Ye BH, Melnick AM, Parekh S.

Oncogene. 2015 Mar 5;34(10):1231-40. doi: 10.1038/onc.2014.44. Epub 2014 Mar 31.


Nordic MCL3 study: 90Y-ibritumomab-tiuxetan added to BEAM/C in non-CR patients before transplant in mantle cell lymphoma.

Kolstad A, Laurell A, Jerkeman M, Grønbæk K, Elonen E, Räty R, Pedersen LB, Loft A, Bogsrud TV, Kimby E, Hansen PB, Fagerli UM, Nilsson-Ehle H, Lauritzsen GF, Lehmann AK, Sundstrom C, Karjalainen-Lindsberg ML, Ralfkiaer E, Ehinger M, Delabie J, Bentzen H, Schildt J, Kostova-Aherdan K, Frederiksen H, Brown Pde N, Geisler CH; Nordic Lymphoma Group.

Blood. 2014 May 8;123(19):2953-9. doi: 10.1182/blood-2013-12-541953. Epub 2014 Mar 20.


High incidence of chronic graft-versus-host disease after myeloablative allogeneic stem cell transplantation for chronic lymphocytic leukemia in Sweden: graft-versus-leukemia effect protects against relapse.

Machaczka M, Johansson JE, Remberger M, Hallböök H, Lazarevic VLj, Wahlin BE, Omar H, Wahlin A, Juliusson G, Kimby E, Hägglund H.

Med Oncol. 2013 Dec;30(4):762. doi: 10.1007/s12032-013-0762-x. Epub 2013 Nov 9.


Waldenstrom's macroglobulinaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Buske C, Leblond V, Dimopoulos M, Kimby E, Jäger U, Dreyling M; ESMO Guidelines Working Group.

Ann Oncol. 2013 Oct;24 Suppl 6:vi155-9. doi: 10.1093/annonc/mdt298. No abstract available.


Searching the haematology and inflammation archives of Journal of Internal Medicine.

Palmblad J, Kimby E.

J Intern Med. 2013 Dec;274(6):541-6. doi: 10.1111/joim.12136. No abstract available.

Supplemental Content

Support Center